ישראל - עברית - Ministry of Health

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 100 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

ישראל - עברית - Ministry of Health

unipharm ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 10 mg - pravastatin

ישראל - עברית - Ministry of Health

truemed ltd, israel - alfacalcidol - קפסולות ג'לטין רכות - alfacalcidol 0.25 mcg - alfacalcidol - alfacalcidol - renal bone disease (renal osteodystrophy), hypoparathyroidism, hyperparathyroidism (with bone disease) - primary and tertiary. neonatal hypocalcemia, rickets and osteomalacia, osteoporosis.

ישראל - עברית - Ministry of Health

truemed ltd, israel - alfacalcidol - קפסולות ג'לטין רכות - alfacalcidol 1 mcg - alfacalcidol - alfacalcidol - renal bone disease (renal osteodystrophy), hypoparathyroidism, hyperparathyroidism (with bone disease) - primary and tertiary. neonatal hypocalcemia, rickets and osteomalacia, osteoporosis.

ישראל - עברית - Ministry of Health

truemed ltd, israel - alfacalcidol - קפסולות ג'לטין רכות - alfacalcidol 0.5 mcg - vitamin d and analogues - renal bone disease . hypoparathyroidisim. rickets and osteomalacia. osteoporosis. primary and tertiary hyperparathyroidism. neonatal hypocalcemia.

ישראל - עברית - Ministry of Health

teva israel ltd - pravastatin sodium - טבליה - pravastatin sodium 40 mg - hmg coa reductase inhibitors - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute coronary events. myocardial infa

ישראל - עברית - Ministry of Health

sanofi israel ltd - clopidogrel as hydrogen sulfate - טבליות מצופות פילם - clopidogrel as hydrogen sulfate 75 mg - clopidogrel - clopidogrel - prevention of atherotrobmotic eventsclopidogrel is indicated in :• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapyprevention of atherotrobmotic and thromboembolic events in atrial fibrillation: in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopid

ישראל - עברית - Ministry of Health

sanofi - aventis israel ltd - clopidogrel as hydrogen sulfate 300 mg - film coated tablets - clopidogrel - prevention of atherotrobmotic eventsclopidogrel is indicated in :• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapyprevention of atherotrobmotic and thromboembolic events in atrial fibrillation: in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopid

ישראל - עברית - Ministry of Health

dexcel ltd, israel - betamethasone as valerate; fusidic acid - קרם - fusidic acid 2 %; betamethasone as valerate 0.1 % - betamethasone and antibiotics - betamethasone and antibiotics - treatment of eczematous dermatoses when secondary bacterial infection is confirmed.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - alitretinoin - קפסולות רכות - alitretinoin 10 mg - alitretinoin - alitretinoin - for use in adults who have severe chronic hand eczema that is unresponsive to treatment with potent topical corticosteroids .patients in whom the eczema has predominantly hyperkeratotic features are more likely to respond to treatment than in those in whom the eczema predominantly presents as pompholyx .